Browse medicines, page 23 of 37

Use listed on the medicine record

Busulfan Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan Injection is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML). ( 1 )

Use listed on the medicine record

The symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate

Use listed on the medicine record

Secondary hyperparathyroidism

Use listed on the medicine record

Carteolol Hydrochloride Ophthalmic Solution 1% has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications.

Use listed on the medicine record

Metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by

Use listed on the medicine record

INDICATIONS & USAGE SECTION Uses Temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: cough due to minor throat and bronchial irritation calms the cough control center and relieves coughing runny nose sneezing itching of the nose and throat itchy, watery eyes

Use listed on the medicine record

The production of local anesthesia by infiltration and peripheral nerve block

Use listed on the medicine record

AnubisMed 50+ Protection Fluid Indications and Usage

Use listed on the medicine record

For use with 3-pump hemodialysisi machines only, using purified water (StandardUNE-EN ISO 23500-3:2019).

Use listed on the medicine record

Mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhali

Use listed on the medicine record

The topical treatment of acne vulgaris

Use listed on the medicine record

Symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and lacrimation

Use listed on the medicine record

Emotional and somatic factors in gastrointestinal disorders

Use listed on the medicine record

Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation

Use listed on the medicine record

Acute or chronic infections due to sensitive strains of certain gram-negative bacilli

Use listed on the medicine record

Menkes disease

Use listed on the medicine record

Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section).

Use listed on the medicine record

XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.

Use listed on the medicine record

Use as a supplement to intravenous solutions given for total parenteral nutrition

Use listed on the medicine record

Cyclobenzaprine hydrochloride extended-release capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion.

Use listed on the medicine record

Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent.

Use listed on the medicine record

Remission induction in acute non-lymphocytic leukemia of adults and pediatric patients

Use listed on the medicine record

Unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test

Use listed on the medicine record

Hodgkin's disease as a secondary-line therapy when used

Use listed on the medicine record

In Chronic Spasticity Dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function.

Use listed on the medicine record

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Use listed on the medicine record

Transfusional iron overload

Use listed on the medicine record

The nasal and non-nasal symptoms of seasonal allergic rhinitis

Use listed on the medicine record

Major depressive disorder (MDD) [see Clinical Studies (14) and Dosage and Administration (2

Use listed on the medicine record

Severe alopecia areata